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During the past decade, intravenous iron supplementation to ESA (erythropoiesis-stimulating agent) therapy has emerged as an
option to augment hemoglobin response in anemic cancer patients. In this paper, the results of seven published randomized
clinical trials assessing the role of iron supplementation to ESA therapy in the hematology/oncology setting will be discussed. The
pathogenetic mechanisms behind functional iron deﬁciency, a major reason for ESA hyporesponsiveness in cancer, will also be
described.
1.Introduction
Recombinant human erythropoietin (rHuEPO) has revolu-
tionized the treatment of anemia associated with chronic
kidney disease (CKD). A few years after the publication
of the trial on rHuEPO treatment in the nephrology
setting by Eschbach and coworkers [1], reports on ESA
treatment of anemia associated with solid tumors as well as
hematologic malignancies were published [2–4]. Although
epoetin and darbepoetin alfa treatment of such patients
increases hemoglobin, reduces transfusion requirements,
relieves symptoms of anemia, and improves health-related
quality of life [5–8], the eﬃcacy is less than that in the
nephrology setting with hemoglobin responses (deﬁned as
an increase in Hb > 20g/L, or Hb increased to 120g/L or
more) typically about 60% [6, 9–11].
A major reason why anemic cancer patients do not
respond to ESAs is functional iron deﬁciency (FID), that is,
failure to provide erythropoiesis with iron despite suﬃcient
iron stores. The mechanism behind FID has been elucidated
in recent years [12, 13]. An inﬂammatory response induced
by conditions such as cancer increases the expression of
the hepatic protein hepcidin in an interleukin-6-dependent
manner [14]. Secreted hepcidin binds to the transmembrane
iron-transporting protein ferroportin in macrophages of the
reticuloendothelial system (RES) as well as in hepatocytes
and in enterocytes and downregulates its expression by
posttranslational mechanisms [15]. In addition to decreased
transport of iron from enterocytes to the circulation, the
downregulated ferroportin expression reduces iron eﬄux
from macrophages [16, 17], thus making less iron available
for erythropoiesis, the ultimate consequence of which is
FID and anemia [18]. FID has also been observed in CKD
patientstreatedwithESAs[19].ThisvariantofFIDcanoccur
without any inﬂammatory response with iron blockage in
macrophages and hepatocytes, but the underlying mecha-
nism is an ESA-driven supraphysiological erythropoiesis in
which the rate-limiting step is the delivery of iron from
its stores to erythroblasts. One way to avoid the relative
iron deﬁciency in FID is the addition of intravenous (i.v.)
iron to ESA therapy, which has been found eﬀective in the
nephrology setting [19]. It has also been shown that i.v. iron
alone raises Hb in anemic CKD patients with FID [20].
For noninvasive diagnosis of FID, the combination of
more than 100µg/L ferritin and less than 20% transferrin
saturation (TSAT) has been proposed [19, 21]. Although
the diagnosis of absolute or functional iron deﬁciency is
straightforward to diagnose in otherwise healthy individuals,
it is often more diﬃcult to diagnose in patients who suﬀer
from cancer, infections, or inﬂammatory diseases since the2 ISRN Hematology
biochemical iron status is aﬀected by acute-phase responses
[22]. Under these circumstances, the best way to assess the
iron status of an individual is to performa bone marrow iron
staining [23]. Thus, in the hematology setting where bone
marrow examination is routinely performed, the optimal
deﬁnition of FID is probably a positive bone marrow iron
staining in combination with TSAT < 20%.
The current American and European hematology/onco-
logy guidelines recommend i.v. iron supplementation to
cancer patients on ESA therapy with iron deﬁciency [24]
and absolute or functional iron deﬁciency [25], respectively,
but do not consider i.v. iron supplementation as a care
standard in this setting. In this paper, I will focus on the
seven published randomized clinical trials (RTCs) assessing
the role of iron supplementation in cancer patients on ESA
therapy [26–32].
2. Characterization of Study Subjects, ESA, and
I r o nDosesasw ellasP r e paratio ns
These seven RCTs were published between 2004 and 2011
and include a total of 1703 patients, the largest reporting
the results for 502 and the smallest for 67 patients [28, 32].
The type of ESA used was darbepoetin in four of the trials
and Epo alfa or Epo beta in the other three. No increase
in ESA dose was allowed in the trials by Auerbach, Bastit
and Steensma, whereas ESA dose escalation was permitted
in the other three trials if no Hb increment of at least 1g/dL
was seen after 4 weeks of treatment [27, 28, 30]. ESA dose
reduction was allowed in all but one of the trials [26]. Six
of the trials excluded patients with absolute iron deﬁciency,
but only the Hedenus trial used positive bone marrow iron
staining as an inclusion criterion [28]. The other 5 trials
used diﬀerent cut-oﬀ points for ferritin and TSAT to exclude
patients with an absolute iron deﬁciency (Table 1). The
Auerbach trial in 2004 probably included patients with an
absolute iron deﬁciency since one inclusion criterion was
ferritin ≤200µg/L or <300µg/L with transferrin saturation
≤19% [26].
Ferric gluconate was used as iron preparation in 4 of
the trials, iron dextran in 2, and iron sucrose in one. The
cumulative dose of intravenous iron in the trials diﬀered
at least four-fold, from 750mg per patient (protocol) in
the Pedrazzoli trial [30] to 3000mg (administered) in the
2004 trial by Auerbach [26]. Iron was withheld in 4 of
the studies if there were biochemical signs of iron overload
[28–31] .T h et r i a lb yH e d e n u sa n dc o w o r k e r s[ 28] included
patientswithlymphoproliferativemalignanciesnotreceiving
chemotherapy only, whereas the other six trials involved
anemic patients with solid malignancies, the most common
being breast, gastrointestinal, and lung cancers, as well as
patients with hematologic malignancies on concomitant
chemotherapy.
3. Summary of Results
In six of the RCTs discussed here, there was a signiﬁcantly
greaterincreaseinHband/oragreaterproportionofpatients
who achieved a hemoglobin response (deﬁned as an increase
in Hb > 20g/L or Hb increase to 120g/L or more or in the
2010 Auerbach trial target Hb ≥ 110g/L) in ESA plus i.v.
iron-treated patients (experimental population) compared
to those treated with ESA plus oral iron or no iron (control
population). Among the six trials with positive results, the
increase in Hb varied from 19 to 29g/L in the experimental
populations compared to 9 to 16g/L in the controls [26–31],
whereas, in the Steensma trial, the increment in Hb was 26
and 24g/L in the experimental and the control populations,
respectively, with no signiﬁcant diﬀerence between them
[32]. The hemoglobin response in the six positive trials
variedfrom68to93percentintheexperimentalpopulations
compared to 25 to 73 percent in controls. In ﬁve of the
trials, the time to achieve a hemoglobin response was
signiﬁcantly shorter in the experimental populations [26,
28–31]. In the Steensma trial, the hemoglobin responses
in the experimental and control populations were 70 and
65%, respectively, a nonsigniﬁcant diﬀerence. Two of the
trials reported that a signiﬁcant greater proportion of
patients with FID (TSAT < 20%) receiving intravenous iron
supplementation achieved a hemoglobin response compared
to those with TSAT > 20% [27, 28]. In all trials reporting
EOTP (end of treatment period) ferritin or change in
ferritin during treatment, ferritin decreased or increased
less in controls compared to the experimental populations
(Table 2). Absence of intravenous iron supplementation led
to decreased EOTP TSAT compared to baseline in 3 of
these trials, whereas this was not observed in the Steensma
trial [32]. The Hedenus and Steensma trials assessed a
possible ESA saving eﬀect of iron supplementation, although
cumulative ESA doses per patient did not diﬀer signiﬁcantly
between the experimental and the control populations [28,
32]. The fraction of patients receiving transfusions with red
blood cells varied from 1 to 25% in the trials, with one of
them showing a signiﬁcantly reduced need for transfusions
in the experimental population compared to control [29].
Quality of life (QoL) was assessed in four of the trials,
but no signiﬁcant positive eﬀects could be detected when
comparing the experimental and the control populations
[26, 29, 31, 32], whereas there was a positive correlation
between Hb increment and positive eﬀects on QoL in the
trials by Auerbach and Steensma irrespective of treatment
group [26, 32]. A suspected higher incidence of severe
adverseeventsinthei.v.ironpopulationintheSteensmatrial
[32] led to its premature termination, whereas acute adverse
events including fatigue, myalgia, and nausea reported in
the other trials were mild, except for 2 cases of iron-related
anaphylactic reactions in the Auerbach 2010 trial [31].
4. Discussion
Although it has been known for many years that i.v. iron
supplementation to ESA therapy can augment hemoglobin
response in the nephrology setting [33, 34], the ﬁrst trial
showing an increased hemoglobin response due to iron
supplementation in anemic cancer patients on ESA therapy
was not published until 2004 [26]. The results of that trialISRN Hematology 3
Table 1: Eligibility criteria (Hb, ferritin, TSAT, bone marrow iron staining) for the seven trials.
Trial Hb (g/L) Ferritin (µg/L) TSAT (%) BM iron
Auerbach 2004 [26] ≤105 ≤200 ≤19∗ ND
Auerbach 2010 [31] ≤100 ≥10 ≥15 ND
Bastit et al. [29] <110 10–800 ≥15 ND
Hedenus et al. [28] 90–110 <800 — +
Henry et al. [27] <110 100–900 15–35 ND
Pedrazzoli et al. [30] <110 100–800 20–40 ND
Steensma et al. [32] <110 ≥20 <60 ND
∗in combination with ferritin <300µg/L. Abbreviations: TSAT, transferrin saturation; ND, not determined; BM iron, bone marrow iron staining; +, positive
bone marrow iron staining.
Table 2: Hemoglobin response (hemoglobin increase >20g/L or to ≥120g/L; in the 2010 Auerbach trial target Hb ≥110 g/L), EOTP ferritin,
and EOTP TSAT for the seven published RCTs comparing ESA ± iron supplementation.
Trial Hemoglobin response (%) EOTP ferritin (µg/L) EOTP TSAT (%)
Auerbach 2004 [26] 25/36/68/68a NR NR
Auerbach 2010 [31] 72/82b 50/539d −0.4/6.7d
Bastit et al. [29] 73/86b NR NR
Hedenus et al. [28] 53/93b 112/400b 20/30b
Henry et al. [27] 41/45/73c −96/−14/344e −14/−2.7/−1.8e
Pedrazzoli et al. [30] 70/93b NR NR
Steensma et al. [32] 65/67/70c 372/426/726c 24/28/24c
acontrol/p.o. iron/bolus doses iron/total dose infusion iron; bcontrol/i.v. iron; ccontrol/p.o. iron/i.v. iron; dmean change control/i.v. iron; emean change
control/p.o. iron/i.v. iron. Abbreviations: EOTP, end of treatment period; TSAT, transferrin saturation; NR, not reported; i.v., intravenous.
have been conﬁrmed by ﬁve other RCTs [27–31]. Previous
trials including anemic cancer patients treated with ESAs
have shown a typical hemoglobin response of about 60%
[6, 9–11], a ﬁgure that increased signiﬁcantly to 68–93%
when ESA was supplemented with i.v. iron [26–31]. In
contrast to the other six trials, the results of the Steensma
trial [32] revealed no improvement in hemoglobin response
after addition of i.v. iron to ESA therapy. There are several
possible explanations for this lack of eﬀect, two of which
will be discussed here. Firstly, the Steensma trial included
subjects with a TSAT of up to 60%. This inclusion criterion
meant that patients with neither absolute nor functional
iron deﬁciency, that is, patients less likely to beneﬁt from
iron supplementation, could be included. Furthermore, the
dose of iron in the Steensma trial might have been too
low to be eﬃcient. The planned total dose of iron in this
trial was the second lowest among the seven published
trials, and the mean actual dose administered was the lowest
[35]. In two of the trials, the hemoglobin response in the
control populations was lower than expected, 25 and 41%,
respectively, probably due to the shorter duration of these
trials [26, 27] and that patients with absolute iron deﬁciency
werenotexcluded[26].Thelowesteﬃcientirondoseinthese
trials was 750 mg administered over 6 weeks [30].
Although there are many hematological and non-hema-
tological beneﬁts of iron [36], there are also safety concerns
about iron supplementation. The most feared acute side
eﬀect of intravenous iron administration is the risk of ana-
phylactic reactions associated with iron dextran prepara-
tions. However, in the nephrology setting, the risk of acute
severe adverse reactions after iron dextran administration is
less than 1% [37]. The risk of anaphylaxis is even smaller
with modern iron preparations [38, 39]. In agreement with
this, the reported incidence of acute severe adverse reactions
associated with intravenous iron in the RCTs discussed here
w a sw e l lb e l o w1 % .
Two of the major concerns about long-term intravenous
iron supplementation are the increased risks of bacterial
infections and vascular damage induced by oxidative stress.
It is known from the pre-rHuEPO era that heavily transfused
CKD patients with biochemical signs of iron overload were
at higher risk of bacterial infections [40, 41]. However, the
epidemiological survey EPIBACDIAL performed after the
advent of rHuEPO treatment could not identify elevated
serum ferritin levels as a risk factor for bacterial infections in
CKD patients [42]. The risk of iron overload after multiple
iron infusions may be prevented by repeated measurements
of ferritin and suspension from the infusions if biochemical
signs of iron accumulation are observed [19]. The other
major concern is that iron supplementation may accelerate
atherosclerosis by oxidative stress, thereby increasing the risk
of renal and cardiovascular morbidity [43, 44]. Intravenous
iron administration in CKD patients leads to a rapid increase
of nontransferrin bound redox-active iron and induces
oxidative stress measured as an increase in lipid peroxidation
[45, 46]. Since the oxidative stress induced by the diﬀerent
commercially available i.v. iron preparations does not seem
to be of similar magnitude [47], it may be possible to reduce
this risk by choosing one of the more stable ones.4 ISRN Hematology
At least in theory, iron administration may decrease
iron mobilization from its stores in FID, since diferric
holotransferrin but not apotransferrin stimulates hepcidin
expression [48]. However, a possible iron-induced hepcidin-
mediated increased sequestration of iron in the RES must
be disregarded due to its positive eﬀects in FID since
i.v. administered iron actually stimulates erythropoiesis in
this condition. In absolute iron deﬁciency, i.v. adminis-
trated iron-carbohydrates rapidly enter RES macrophages,
where they are processed, thus releasing iron from these
cells and delivering it to erythroblasts by transferrin. In
cancer patients, less iron may be delivered from the RES
macrophages to erythroblasts [49, 50]. Since a fraction
of iron in the iron-carbohydrate complex directly binds
transferrin[51],itispossiblethatthisfraction,whichescapes
sequestration in RES, mediates its biological eﬀect in FID.
5. Concluding Remarks
SixofthesevenRCTsdiscussedhereshowanaugmentedery-
thropoietic response in anemic ESA-treated cancer patients
receiving i.v. iron supplementation compared to those not
receiving iron. This eﬀect was observed in patients with
absolute iron deﬁciency, those who fulﬁlled the FID criteria
as well as in those who did not.
Intravenous iron supplementation should be strongly
considered in anemic cancer patients treated with ESAs,
since its positive eﬀect on hemoglobin response has been
documented in six published RCTs [26–31], two RCTs in
abstract form [52, 53], and two meta-analyses [54, 55].
However, the preferred iron preparation, optimal dose of
iron, and dosing schedule are currently not known.
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